MedTrace Logo

Low Dose Naltrexone (LDN) Immune Monitoring

NCT02107014 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2017-04-11

Study results available
· View outcomes & findings →

Summary

We have found that low dose naltrexone (LDN) can substantially reduce pain associated with fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The purpose of this study is to determine if LDN lowers inflammatory markers in individuals with fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

DRUG

Low Dose Naltrexone

Naltrexone 4.5 mg p.o. nocte

Sponsors & Collaborators

Principal Investigators

  • Jarred Younger, PhD · University of Alabama at Birmingham

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02107014 on ClinicalTrials.gov